Short-squeeze stocks grabbed headlines last year following the monumental meme stock frenzy in 2021. The phenomenon emerged from the trenches of Reddit where traders banded together leaving short-sellers scrambling to cover their positions. In the blink of an eye, these stocks witnessed massive price jumps, defying investing logic. Since then, meme stocks have become part
0 Comments
Chip stocks probably will stage a recovery this year. In the latter part of 2022, the semiconductor industry experienced significant declines because of a drop in demand for chip products based on technology. However, recent trends indicate the sector is regaining momentum and returning with a bang. The technology sector heavily relies on the chip
0 Comments
Mullen Automotive (NASDAQ:MULN) stock is once again making headlines, but these latest developments aren’t being met with much excitement based on recent price action. In the past few weeks, this early-stage electric vehicle manufacturer has hit a major milestone. The company has closed on a large financing deal. Shares have barely budged on this news.
0 Comments
Investors looking for the best cannabis stocks may be curious whether any of the more high-profile names are buying opportunities. After all, since the sector fell out of favor, once-popular plays like Canopy Growth (NASDAQ:CGC) and SNDL (NASDAQ:SNDL) have fallen to rock-bottom prices. But after some digging, I found some that could see higher highs.
0 Comments
Typically, blue-chip stocks to buy don’t attract attention for their sheer upside potential. Rather, these enterprises bank on their established businesses to provide steady rewards for their stakeholders. In perhaps most cases, we’re talking about a modest combination of passive income and capital gains. However, a select few stalwarts may be capable of doubling their
0 Comments
Although society at large looked forward to a broader normalization cycle, the sudden interest in energy-related dividend stocks to buy signaled that the post-pandemic paradigm still has serious bite. Earlier this month, the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — surprised the world with a shock
0 Comments
It’s been 19 months since Trump Media and Technology Group (TMTG) and Digital World Acquisition (NASDAQ:DWAC) announced they were merging to form a media colossus to gather subscribers for its Truth Social stock social media platform. Along the way, the DWAC shot would hit an all-time high of $101.87 on March 2, 2022. Unfortunately, it’s been
0 Comments
So, it’s settled: Canadian cannabis producer Tilray (NASDAQ:TLRY) plans to acquire rival Hexo (NASDAQ:HEXO). It’s debatable, however, whether this is actually a good idea. In the same press release, Tilray disclosed its financial results for the third quarter of fiscal 2023. Suffice it to say, the data doesn’t look promising, and it’s not a good
0 Comments
As public opinion continues to shift, investors are starting to look a which cannabis stocks to buy.  Sure, we’re still waiting on federal legalization and possible rescheduling, but as we wait, more states are moving forward and more than 91% of Americans want to see legalization. Abroad, it looks likely Germany will introduce a bill
0 Comments
Most readers will be aware of the virtues blue-chip stocks possess: They’re large, well-established companies with a financially sound business that lends great credibility to their equity in general. These companies are household names with track records of steady growth and operational profitability in some cases over decades. They’ve weathered economic cyclicality and the recessions that come
0 Comments
You just never know what Vinco Ventures (NASDAQ:BBIG) might do next. The company is truly unpredictable, but Vinco Ventures’ adventurous spirit won’t be enough to save BBIG stock. Don’t be too surprised if Vinco Ventures ends up on an over-the-counter (OTC) exchange at some point. I’ll admit that Vinco Ventures is full of interesting business ideas.
0 Comments
After recently reporting strong clinical data, Novavax (NASDAQ:NVAX) has tremendous opportunities in front of it. More specifically, the company’s coronavirus booster and its coronavirus-flu combination vaccine can become huge revenue generators. Given these points, I believe that NVAX stock can soar almost 12 times within the next year. The company’s new CEO also makes me very upbeat
0 Comments